Table 1.
Baseline patient characteristics
| Characteristics | Patients (N=25) | % |
| Age at enrollment (years) | ||
| Median (range) | 59 (33–78) | |
| <60 years | 13 | 52 |
| ≥60 years | 12 | 48 |
| Sex | ||
| Female | 18 | 72 |
| Male | 7 | 28 |
| Eastern Cooperative Oncology Group performance status | ||
| 0 | 0 | 0 |
| 1 | 25 | 100 |
| Tumor histology | ||
| Adenocarcinoma | 9 | 36 |
| Undifferentiated carcinoma | 14 | 56 |
| Squamous cell carcinoma | 2 | 8 |
| Time to trial since first diagnosis (years) | ||
| Median (range) | 0.9 (0.3–4.5) | |
| <6 months | 6 | 24 |
| 6 months–1 year | 8 | 32 |
| 1 year–2 years | 5 | 20 |
| ≥2 years | 6 | 24 |
| Number of previous anticancer lines of treatment | ||
| Median (range) | 2 (1–5) | |
| 1 | 8 | 32 |
| 2 | 7 | 28 |
| 3 | 4 | 16 |
| 4/5 | 6 | 24 |
| Mismatch-repair (MMR)/microsatellite status (N=11) | ||
| Proficient-MMR/microsatellite-stable | 11 | 100 |
| Deficient-MMR/microsatellite-instability high | 0 | 0 |
| PD-L1 status (H-score) | ||
| 0 | 9 | 36 |
| 1–150 | 12 | 48 |
| 150–300 | 4 | 16 |
| PD-L1 expression status* | ||
| Positive | 9 | 36 |
| Negative | 16 | 64 |
| Tumor infiltrating lymphocytes (TILs) infiltration score | ||
| 0 (no TILs) | 1 | 4 |
| 1 (few TILs) | 11 | 44 |
| 2 (moderate infiltration of TILs) | 4 | 16 |
| 3 (intense infiltration of TILs) | 9 | 36 |
*Programmed cell death ligand-1 (PD-L1) expression was considered positive if immunohistochemistry was 3+ or 2+ in ≥5% cells.